A nontricyclic heterocyclic antidepressant.
Probably works by inhibiting the reuptake of dopamine and norepinephrine and increasing the amounts of both neurotransmitters to bind to their respective receptors in the CNS.
Useful in patients that can not tolerate the effects of tricyclic antidepressants.
Contraindicated in patients with seizure disorders and anorexia and in patients taking monoamine oxidase inhibitors.
Use doubles the long-term smoking cessation rate.
More effective than nicotine relacement therapy for ambulatory cessation in the general population.
In hospitalized patients with acute coronary syndrome who received intensive nurse counseling for smoking cessation, bupropion did not increase the rates of smoking abstinence at 1 year (Planer D et al).
Safe and effective in patients with stable cardiovascular disease.
Most common adverse effects are insomnia and dry mouth.
Insomnia occurs in 30-45% of individuals.
May be associated with urticaria.
Incidence rate of seizures is approximately 0.1% to 0.4%.
Rash 0.1% of patients.